Samrat Pharmachem (BOM:530125) Cyclically Adjusted PB Ratio: (As of Sep. 08, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:530125 Samrat Pharmachem Ltd BOM:530125
69 GF Score
Price ₹229.90
GF Value ₹355.67
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Samrat Pharmachem Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Samrat Pharmachem  (BOM:530125) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Samrat Pharmachem Cyclically Adjusted PB Ratio Related Terms


Samrat Pharmachem Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Samrat Pharmachem's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Samrat Pharmachem Cyclically Adjusted PB Ratio Chart

Samrat Pharmachem Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.22 3.89 2.94 2.36 1.27

Samrat Pharmachem Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 2.02 0.00 1.27 0.00

BOM:530125 vs DOW: Cyclically Adjusted PB Ratio Comparison

For the Chemicals subindustry, Samrat Pharmachem's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Samrat Pharmachem Cyclically Adjusted PB Ratio vs Chemicals Industry

For the Chemicals industry and Basic Materials sector, Samrat Pharmachem's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Samrat Pharmachem's Cyclically Adjusted PB Ratio falls into.


BOM:530125
69GF Score
Samrat Pharmachem Ltd BOM:530125
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Samrat Pharmachem Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Samrat Pharmachem's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Samrat Pharmachem's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0/167.3573*167.3573
=0.000

Current CPI (Jun. 2026) = 167.3573.

Samrat Pharmachem Quarterly Data

Book Value per Share CPI Adj_Book
201609 46.674 105.961 73.718
201612 0.000 105.196 0.000
201703 49.561 105.196 78.847
201706 0.000 107.109 0.000
201709 53.304 109.021 81.826
201712 0.000 109.404 0.000
201803 59.972 109.786 91.421
201806 0.000 111.317 0.000
201809 59.815 115.142 86.940
201812 0.000 115.142 0.000
201903 64.941 118.202 91.947
201906 0.000 120.880 0.000
201909 75.857 123.175 103.067
201912 0.000 126.235 0.000
202003 78.653 124.705 105.554
202006 0.000 127.000 0.000
202009 85.895 130.118 110.478
202012 0.000 130.889 0.000
202103 95.912 131.771 121.815
202106 0.000 134.084 0.000
202109 108.026 135.847 133.083
202112 0.000 138.161 0.000
202203 151.527 138.822 182.674
202206 0.000 142.347 0.000
202209 200.974 144.661 232.505
202212 0.000 145.763 0.000
202303 204.348 146.865 232.862
202306 0.000 150.280 0.000
202309 204.716 151.492 226.155
202312 0.000 152.924 0.000
202403 210.346 153.035 230.033
202406 0.000 155.789 0.000
202409 224.643 157.882 238.125
202412 0.000 158.323 0.000
202503 232.363 157.552 246.825
202506 0.000 159.755 0.000
202509 228.722 162.289 235.865
202512 0.000 163.281 0.000
202603 220.645 164.272 224.789
202606 0.000 167.357 0.000

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Samrat Pharmachem (BOM:530125) Overvalued in 2026?

Based on GuruFocus' analysis, Samrat Pharmachem stock appears to be undervalued. The current stock price of ₹229.90 is trading 35.4% below its estimated GF Value™ of ₹355.67. GuruFocus considers Samrat Pharmachem to be Possible Value Trap.

Key valuation signals for BOM:530125:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: ₹355.67 vs. price of ₹229.90 (35.4% below fair value)
  • GF Score™: 69/100 with 4 warning signs

No single metric tells the full story. See the BOM:530125 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Samrat Pharmachem Business Description

Address M. A. Road, 701/702, Business Square, Andheri (West), Mumbai, MH, IND, 400 058
Samrat Pharmachem Ltd is a producer of pharmaceutical chemicals. The principal activity of the company is to manufacture Iodine salts and bromine salts. Its product portfolio consists of potassium iodate, potassium iodide, methyl iodide, and copper iodide. Its products are used in various industries like pharmaceuticals and chemicals.
69GF Score

Get the complete analysis for BOM:530125

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹229.90
Price
₹355.67
GF Value